Table 1.
Observation | Niraparib maintenance | |||
---|---|---|---|---|
Patient cohort | PFS (months) | Utility* | PFS (months) | Utility* |
All patients | 4.22 | .83 | 11.64 | .84 |
Germline BRCA1/2 mutant | 5.5 | .83 | 21 | .84 |
Germline BRCA wild type | 3.9 | .83 | 9.3 | .84 |
HRD testing, positive | 3.8 | .83 | 12.9 | .84 |
HRD testing, negative | 3.8 | .83 | 6.9 | .84 |
Utility scores adapted from the European Quality of Life scale, 5-Dimensions (EQ-5D-5L) measurements from NOVA trial, Mirza et al. 2016